My watch list
my.bionity.com  
Login  

Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system

Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system

Nature Reviews Drug Discovery 10, 648 (2011). doi:10.1038/nrd3537

Bristol-Myers Squibb has acquired exclusive global rights to Innate Pharma's cancer candidate IPH 2102, which is in Phase I clinical trials for acute myeloid leukaemia (AML). Innate Pharma will receive US$35 million upfront and is eligible to receive up to $430 million in milestones.IPH

Journal:   Nature Reviews Drug Discovery
Year:   2011
DOI:   10.1038/nrd3537
Publication date:   31-08-2011
More about Nature Publishing Group
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE